Abstracts tagged "glucocorticoids"

Abstract Number: 2723 • 2018 ACR/ARHP Annual Meeting
Patient Experience in ANCA-Associated Vasculitis Evolves over Time from Diagnosis and Both Benefits and Adverse Impacts Are Felt with Current Therapy
Peter Rutherford¹, Dieter Goette¹, James O`Donoghue² and Xierong Liu², ¹Medical Affairs, Vifor Pharma, Zurich, Switzerland, ²Elma Research, London, United Kingdom
Background/Purpose: ANCA-associated vasculitis (AAV) leads to both acute illness and a long-term condition in which the disease remits and relapses. Therapy is often complex and…
Abstract Number: 885 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster in Tofacitinib Users with and without Concomitant Methotrexate and Glucocorticoids
Jeffrey R. Curtis¹, Fenglong Xie¹, Sasha Bernatsky², Shuo Yang¹, Lang Chen¹, Huifeng Yun¹ and Kevin Winthrop³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Rheumatology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Oregon Health and Science University, Portland, OR
Background/Purpose: An increased incidence of herpes zoster (HZ) has been observed with Janus kinase inhibitors such as tofacitinib (TOF). However, among TOF users, a potentially…
Abstract Number: 1235 • 2018 ACR/ARHP Annual Meeting
Isoniazid Monotherapy As a Prophylaxis for Tuberculosis in Patients with Rheumatic Diseases Exposed to Prolonged, High-Dose Glucocorticoids
Jun Won Park¹, Jeffrey R. Curtis², Hajeong Lee³, Yeong Wook Song⁴ and Eun Bong Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁴Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Although use of glucocorticoid increases the risk of tuberculosis (TB) disease, there has been few studies investigating its incidence and risk/benefit assessment of the…
Abstract Number: 1633 • 2018 ACR/ARHP Annual Meeting
Fragility Fractures in Psoriatic Arthritis Patients: A Matched-Control Study
Luciano Fernando Lo Giudice¹, Marina Scolnik², Florencia Pierini³, Nicolas Martin Marin Zucaro¹, John Fredy Jaramillo Gallego¹ and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina
Background/Purpose: patients with Psoriatic Arthritis (PsA) in spite of having bone production as one of their characteristic features, very often have osteoporosis, but scarce data…
Abstract Number: 1767 • 2018 ACR/ARHP Annual Meeting
Occurrence and Etiology of Gastrointestinal Perforation in Patients with Vasculitis
Vanessa L. Kronzer¹, Daniel Larson², Cynthia S. Crowson^3,4, Kenneth J. Warrington⁵, Steven R. Ytterberg⁵, Ashima Makol⁴ and Matthew J. Koster⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pathology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: This study aimed to characterize the presenting features and outcomes of patients with small- or medium-vessel vasculitis and gastrointestinal perforation. Methods: Using a retrospective…
Abstract Number: 1889 • 2018 ACR/ARHP Annual Meeting
Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population
Beth Wallace^1,2,3, Paul Lin^2,4, Neil Kamdar^2,4, Mohamed Noureldin^2,3,5, Rodney Hayward^2,3,6, David A. Fox¹, Jeffrey R. Curtis⁷, Kenneth Saag⁸ and Akbar Waljee^2,3,9, ¹Department of Internal Medicine, Division of Rheumatology, Michigan Medicine, Ann Arbor, MI, ²University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, MI, ³Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁴University of Michigan Medical School, Ann Arbor, MI, ⁵Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁶Department of Internal Medicine, Division of General Medicine, Michigan Medicine, Ann Arbor, MI, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama, Birmingham, AL, ⁹Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Glucocorticoids (GC) reduce RA-related disability and joint damage; RA guidelines endorse short term use during DMARD initiation and flares. Long-term high-dose GC exposure (>3…
Abstract Number: 2141 • 2018 ACR/ARHP Annual Meeting
Development of a Pediatric Glucocorticoid Toxicity Index
Paul Brogan¹, Raymond P. Naden², Stacy P. Ardoin³, Jennifer C. Cooper⁴, Fabrizio De Benedetti⁵, Jean-Francois Dicaire⁶, Despina Eleftheriou⁷, Brian M. Feldman⁸, Jon Goldin⁹, Seth E. Karol¹⁰, Eli Miloslavsky¹¹, Fiona Price-Kuehne¹², David Skuse⁹, Constantine A. Stratakis¹³, Nicholas Webb¹⁴ and John H. Stone¹⁵, ¹Infection Inflammation and Rheumatology, UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ³The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁶Pinnacle Inc., Quebec, QC, Canada, ⁷Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁸Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁹Psychiatry, Great Ormond Street Hospital / University College London, London, United Kingdom, ¹⁰Oncology, St. Jude's Children's Hospital, Memphis, TN, ¹¹Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹²Rheumatology, Cambridge University Hospitals, Cambridge, United Kingdom, ¹³National Institute of Child Health and Human Development, Bethesta, MD, ¹⁴Pediatrics, Manchester University, Manchester, United Kingdom, ¹⁵Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: A Glucocorticoid Toxicity Index app (GTI 2.0) is now used as a clinical trial outcome measure in adults, but glucocorticoid (GC) toxicity issues in…
Abstract Number: 2172 • 2018 ACR/ARHP Annual Meeting
Overuse of Glucocorticoids in Rheumatoid Arthritis: A National Survey of Primary Care Physicians
Beth Wallace^1,2, Akbar Waljee^2,3,4, Arlene Weissman⁵, Tanner Caverly^2,6,7 and Sameer Saini^2,6,8, ¹Department of Internal Medicine, Division of Rheumatology, Michigan Medicine, Ann Arbor, MI, ²University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, MI, ³Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁴Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI, ⁵Research Center at American College of Physicians, Philadelphia, PA, ⁶Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, ⁷Michigan Medicine Department of Internal Medicine, Division of General Medicine, Ann Arbor, MI, ⁸Michigan Medicine Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, MI
Background/Purpose: Most patients with RA receive oral glucocorticoids (GC) such as prednisone, despite concerns about safety. We sought to evaluate how primary care physicians (PCPs)…
Abstract Number: 1624 • 2017 ACR/ARHP Annual Meeting
SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K
Zahi Touma¹, Dafna D Gladman², Jiandong Su³, Nicole Anderson⁴ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) is one of the most commonly used disease activity indices in clinical practice and research but this…
Abstract Number: 2043 • 2017 ACR/ARHP Annual Meeting
Adherence to American College of Rheumatology Guidelines for Prevention of Glucocorticoid-Induced Osteoporosis in Patients with Polymyalgia Rheumatica
Brittany Frankel¹, Angela Christensen² and Monica Guma³, ¹Internal Medicine, University of California, San Diego, San Diego, CA, ²Rheumatology, University of California, San Diego, San Diego, CA, ³University of California, San Diego, San Diego, CA
Background/Purpose: American College of Rheumatology (ACR) 2010 guidelines recommend that any patient initiating glucocorticoid therapy with an anticipated duration of ≥3 months should receive a…
Abstract Number: 2279 • 2017 ACR/ARHP Annual Meeting
Dynamics of Concomitant Therapy in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Ekaterina Alexeeva^1,2, Tatiana Dvoryakovskaya^1,2, Victor Gladkikh^3,4, Andrei Moskalev^4,5, Rina Denisova², Ksenia Isaeva², Olga Lomakina², Margarita Soloshenko² and Anna Karaseva², ¹Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, ²Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ³Department of Biostatistics, EOL Labs ltd, Novosibirsk, Rwanda, ⁴Laboratory of Computational Physics, Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russian Federation, ⁵Department of Biostatistics, EOL Labs ltd, Novosibirsk, Russian Federation
Background/Purpose: The effectiveness of target use of biological medications depends on how personalized they are to fit patient’s individual parameters with juvenile idiopathic arthritis (JIA).…
Abstract Number: 2367 • 2017 ACR/ARHP Annual Meeting
The Effect of Glucocorticoids on Bone Mineral Density in Patients with Rheumatoid Arthritis: a Systematic Review and Meta-Analysis
Anne-Birgitte Blavnsfeldt^1,2, Malissa Dawn Thomsen³, Simon Tarp⁴, Bente Langdahl^2,5, Ellen-Margrethe Hauge^2,6 and Annette de Thurah^7,8, ¹Rheumatology, Aarhus Universityhospital, Aarhus C, Denmark, ²Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark, ³Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, ⁴The Parker Institute, Bispebjerg & Frederiksberg Hospital, Copenhagen, Denmark, ⁵Endocrinology, Aarhus University Hospital, Aarhus, Denmark, ⁶Aarhus Universityhospital, Aarhus C, Denmark, ⁷Department of Rheumatology, Aarhus University Hospital, Aarhus, DK, Aarhus, Denmark, ⁸Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: The role of glucocorticoids (GCs) in the treatment of rheumatoid arthritis (RA) is widely debated. GCs stimulate bone resorption and impair bone formation. Inflammatory…
Abstract Number: 2654 • 2017 ACR/ARHP Annual Meeting
Treatment-Associated DNA Methylation Patterns in Systemic Lupus Erythematosus
Juliana Imgenberg-Kreuz^1,2, Jonas Carlsson Almlöf¹, Dag Leonard³, Gunnel Nordmark², Maija-Leena Eloranta³, Leonid Padyukov⁴, Iva Gunnarsson⁴, Elisabet Svenungsson⁴, Christopher Sjöwall⁵, Lars Rönnblom², Ann-Christine Syvänen¹ and Johanna K Sandling^1,2, ¹Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ²Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ³Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ⁴Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁵Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping University, Linköping, Sweden, Linköping, Sweden
Background/Purpose: DNA methylation has emerged as an important contributing factor in the pathogenesis of systemic lupus erythematosus (SLE). SLE typically requires continuous treatment to control…
Abstract Number: 212 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Large Vessel Arteritis (Giant Cell Arteritis and Temporal Arteritis): Findings from a Large Contemporaneous Real-World Cohort in the US
Zhaohui Su¹, Vandana Menon¹, Richard Gliklich² and Tom Brecht¹, ¹Research, OM1, Inc, Cambridge, MA, ²OM1, Inc, Cambridge, MA
Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary systemic vasculitis with annual incidence as high as 27 per 100,000 in persons…
Abstract Number: 793 • 2017 ACR/ARHP Annual Meeting
Metotrexate in the Treatment of Giant Cell Arteritis: To be or Not to be
Ignacio Castaño¹, Irene Monjo², Alejandro Balsa³, Diana Peiteado², Sara García-Carazo⁴ and Eugenio De Miguel¹, ¹Medicine, Universidad Autonoma Madrid, MADRID, Spain, ²Rheumatology, Hospital Universitario La Paz, MADRID, Spain, ³Rheumatology, Hospital La Paz-IdiPAZ, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: The high-dose glucocorticoids (GCs) are the mainstay of treatment in Giant Cell Arteritis (GCA). Patients treated with greater GC dosages are at the greatest…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.